About Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist used in metabolic research. Supplied as a lyophilized powder for laboratory studies investigating dual incretin receptor activation, insulin-related signaling pathways, and glucose homeostasis mechanisms in controlled experimental models. Each batch undergoes analytical verification for identity and purity using HPLC and mass spectrometry. Supplied as: Lyophilized powder Purity: >95-99 (HPLC verified) Storage: Store desiccated at ?20�C for long-term. Short-term room temperature exposure (around 1 month) during shipping/handling is generally acceptable if kept sealed, dry, and protected from heat/light. Designation: FOR RESEARCH USE ONLY. Not intended for human or animal consumption.
Latest Research
Enhancing economic modelling in obesity: integrating novel type 2 diabetes progression & obstructive sleep apnea remission - a UK case study.
Recent research on Tirzepatide: Enhancing economic modelling in obesity: integrating novel type 2 diabetes progression & obstructive sleep apnea remission - a UK case study.
Read Full Study on PubMedDNA-based delivery of incretin receptor agonists using MYO Technology leads to durable weight loss in a diet-induced obesity model.
Recent research on Tirzepatide: DNA-based delivery of incretin receptor agonists using MYO Technology leads to durable weight loss in a diet-induced obesity model.
Read Full Study on PubMedAdditional Studies
ICER report demonstrates both the value and challenges in financing of weight loss medications.
Recent research on Tirzepatide: ICER report demonstrates both the value and challenges in financing of weight loss medications.
Read on PubMedJoint TOS/OMA/OAC expert guidance statement on the pharmacological management of United States adults with overweight or obesity using the GRADE approach.
Recent research on Tirzepatide: Joint TOS/OMA/OAC expert guidance statement on the pharmacological management of United States adults with overweight or obesity using the GRADE approach.
Read on PubMedGLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling.
Recent research on Tirzepatide: GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling.
Read on PubMedTargeting Inflammation and Fibrosis in Lipedema: The Potential Role of Glucagon-like Peptide-1 Receptor Agonist Therapies.
Recent research on Tirzepatide: Targeting Inflammation and Fibrosis in Lipedema: The Potential Role of Glucagon-like Peptide-1 Receptor Agonist Therapies.
Read on PubMedThe Role of Glucagon-Like Peptide-1 Receptor Agonists in Hair Loss: Clinical Evidence and Proposed Mechanisms.
Recent research on Tirzepatide: The Role of Glucagon-Like Peptide-1 Receptor Agonists in Hair Loss: Clinical Evidence and Proposed Mechanisms.
Read on PubMedGLPs Significantly Decrease the Risk of Postoperative Surgical Complications: A TriNetX Retrospective Cohort Study.
Recent research on Tirzepatide: GLPs Significantly Decrease the Risk of Postoperative Surgical Complications: A TriNetX Retrospective Cohort Study.
Read on PubMedRelated Research
Purchase Tirzepatide from Verified Peptides
High-purity research peptides with full analytical verification
- 99% Purity (HPLC Verified)
- Full Certificate of Analysis
- Same Day Dispatch
- Free UK Shipping Over £75
Research Disclaimer
The research articles and studies referenced on this page are for informational purposes only. All products are sold for research use only and are not intended for human or animal consumption. The information provided does not constitute medical advice, diagnosis, or treatment. Always consult with qualified healthcare professionals before making any decisions related to health or medical treatment.